July 2008 Oncology News International

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

William R. Kennedy, MD

Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.

Russ Conroy

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

David J. Portman;Matthew P. Goetz, MD;Seth A. Wander;Thomas Bachelot;Guiseppe Curigliano;Alexandre de Nonneville;Einav Nili Gal-Yam;Sarah Sammons, MD;Sherry Shen, MD;Christ Twelves;Paul V. Plourde;Senthil Damodaran

Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Roman Fabbricatore

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Related Content

Tim Cortese

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD

Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Russ Conroy

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

Roman Fabbricatore